Adalimumab is a biological agent, one of the tumour necrosis factor-alpha 
inhibitors. Pivotal studies evaluating its efficacy in plaque psoriasis 
(CHAMPION, REVEAL) and psoriatic arthritis (PsA) (ADEPT) were carried out in 
recent years. Adalimumab proved highly effective in psoriasis patients and in 
PsA patients previously unresponsive to nonsteroidal anti-inflammatory drugs. 
Results of smaller studies suggest therapy with the drug may be successful in 
psoriasis resistant to other biologics and PsA unresponsive to disease-modifying 
antirheumatic drugs. Adalimumab has also been shown to improve patients' quality 
of life significantly. Although they should be further extended as far as 
dermatological conditions are concerned, available data indicate adalimumab is 
safe and well tolerated. Numerous case reports featuring its off-label use 
suggest the drug could be helpful in treating hidradenitis suppurativa, pyoderma 
gangrenosum, Sweet's syndrome, cutaneous sarcoidosis, pemphigus, systemic 
vasculitides, multicentric reticulohistiocytosis and stomatitis.